Human umbilical cord blood-derived stromal cells: A new resource for the proliferation and apoptosis of myeloma cells

References

• Gao L, Chen X, Zhang X, Liu Y, Kong P, Peng X, et al. Human umbilical cord blood-derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34+ cells in vitro. Blood Cell Mol Dis 2006;36:322–8.
   PubMed Web of Science ®Google Scholar
• Méndez-Ferrer S, Frenette PS. Hematopoietic stem cell trafficking: regulated adhesion and attraction to bone marrow microenvironment. Ann N Y Acad Sci. 2007;11(16):392–413.
   Google Scholar
• Feng Y, Wen J, Mike P, Choi DS, Eshoa C, Shi ZZ, et al. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev. 2010;19(9):1289–96.
   PubMed Web of Science ®Google Scholar
• Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009;10(3):345–6.
   PubMed Web of Science ®Google Scholar
• Fowler JA, Edwardsa CM, Croucherb PI. Tumor–host cell interactions in the bone disease of myeloma. Bone 2011;48:121–8.
   PubMed Web of Science ®Google Scholar
• Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD, et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009;113(20):4894–902.
   PubMed Web of Science ®Google Scholar
• Zdzisińska B, Bojarska-Junak A, Walter-Croneck A, Kandefer-Szerszeń M. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients’ bone marrow stromal cells co-cultured with myeloma cells. Arch Immunol Ther Exp. (Warsz) 2010;58(2):153–63.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells. Mol Cancer. 2010;9:176–89.
   PubMed Web of Science ®Google Scholar
• Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116(17):3227–37.
   PubMed Web of Science ®Google Scholar
• Zdzisiñska B, Roliñski J, Piersiak T, Kandefer-Szerszeñ M. A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of muliple myeloma patients in response to RPMI8226 myeloma cells. Folia Histochem Cytobiol. 2009;47(1):69–74.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, et al. Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009;113(21):5228–36.
   PubMed Web of Science ®Google Scholar
• Mahtouk K, Moreaux J, Hose D, Rème T, Meißner T, Jourdan M, et al. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010;10:198.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005;18:509–24.
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, Moreau A-S, Azab F, Leleu X, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113(18):4341–51.
   PubMed Web of Science ®Google Scholar
• Monika E, Roland M. 160 years of multiple myeloma: progress and challenges. Eur J Cancer 2006;42:1507–9.
   PubMed Web of Science ®Google Scholar
• Gao L, Chen X-H, Feng Y-M, Zhang X, Yu S-C, Gao L, et al. Human umbilical cord blood-derived stromal cells Multifaceted regulators of megakaryocytopoiesis. Cell Cycle 2010;9(7):1–12.
   PubMed Web of Science ®Google Scholar
• Feng Y, Chen X, Gao L. Hypothesis: human umbilical cord blood-derived stromal cells promote megakaryocytopoiesis through the influence of SDF-1 and PECAM-1. Cell Biochem Biophys. 2010;58:25–30.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yi L, Zhang X, Gao L, Zhang C, Feng Y-M, et al. Cotransplantation of human umbilical cord blood-derived stromal cells enhances hematopoietic reconstitution and engraftment in irradiated BABL/c mice. Cancer Biol Ther. 2010;11(1):1–11.
   Web of Science ®Google Scholar
• Liang X, Hao L, Chen X, Zhang X, Kong P, Peng X, et al. Effects of bone marrow stromal cells and umbilical cord blood-derived stromal cells on daunorubicin-resistant residual Jurkat cells. Transplant Proc. 2010;42:3767–72.
   PubMed Web of Science ®Google Scholar
• Zhang C, Chen X-H, Zhang X, Gao L, Kong PY, Peng XG, et al. Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stemcell transplantation in sublethally irradiated mice. J Biol Chem. 2011;286(15):13723–32.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang X, Gao L, Chen XH. Effect of stromal cells derived from different origins on proliferation and apoptosis of KM3 cells. Acta Acad Med Militaris Tertiae 2009;31(10):879–82.
   Google Scholar
• Pellegrino A, Ria R, Di Pietro G, Cirulli T, Surico G, Pennisi A. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol. 2005;129:248–56.
   PubMed Web of Science ®Google Scholar
• Feng Y, Ofek G, Soon Choi D, Wen J, Hu J, Zhao H, et al. Unique biomechanical interactions between myeloma cells and bone marrow stroma cells. Prog Biophys Mol Biol. 2010;103:148–56.
   PubMed Web of Science ®Google Scholar
• Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006;195:173–83.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, et al. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw. 2005;16(1):57–64.
   PubMed Web of Science ®Google Scholar
• Zdzisińska B, Bojarska-Junak A, Dmoszyńska A, Kandefer-Szerszeń M. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp. (Warsz) 2008;56(3):207–21.
   PubMed Web of Science ®Google Scholar
• Arnulf B, Lecourt S, Soulier J, Lacassagne MN, Crinquette A, Dessoly J, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007;21:158–63.
   PubMed Web of Science ®Google Scholar
• Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101:2775–83.
   PubMed Web of Science ®Google Scholar
• Kovacs E. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Biomed Pharmacother. 2003;57:489–94.
   PubMed Web of Science ®Google Scholar
• Lasfar A, Wietzerbin J, Billard C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur J Immunol. 1994;24:124–30.
   PubMed Web of Science ®Google Scholar
• Thabard W, Collette M, Mellerin M-P, Puthier D, Barillé S, Bataille R, et al. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine. 2001;14(6):352–6.
   PubMed Web of Science ®Google Scholar
• Conticelloa C, Giuffridab R, Adamob L, Anastasi G, Martinetti D, Salomonec E, et al. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res. 2011;35:52–60.
   PubMed Web of Science ®Google Scholar